Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
NCT04030169 · MAPS Europe B.V.
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Change in CAPS-5 Total Severity Score
Measured over 13 weeks post-baseline
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
6 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| NUDZ - National Institute of Mental Health | Klecany | Central Bohemia | Czechia |
| Charité - Universitätsmedizin, Berlin Campus Benjamin Franklin | Berlin | — | Germany |
| Stichting Centrum '45/Arq | Oegstgeest | Noord Holand | Netherlands |
| Sykehuset Østfold Hf, DPS Norder | Moss | — | Norway |
| University Hospital of Wales - Research Facility | Cardiff | — | United Kingdom |
| The Institute of Psychiatry, Psychology and Neuroscience | London | — | United Kingdom |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT04030169 on ClinicalTrials.gov →
Last updated in the registry 2025-01-28. Registry records change; this page reflects the data build of 2026-08-25.
Related
Where this trial sits
Substance
Indication